Țară: Irlanda
Limbă: engleză
Sursă: HPRA (Health Products Regulatory Authority)
ARIPIPRAZOLE
EGIS Pharmaceuticals PLC
N05AX12
ARIPIPRAZOLE
15 Milligram
Tablets
Product subject to prescription which may not be renewed (A)
aripiprazole
Not Marketed
2016-02-26
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Alcartis 15 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 15 mg aripiprazole. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet White or almost white, round, flat, bevelled edge tablets with stylized E and 563 code on one side and no engraving on the other side. The diameter of the tablet is about 9 mm. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Alcartis is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Alcartis is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1). Alcartis is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults:_ _Schizophrenia:_ the recommended starting dose for Alcartis is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals. Alcartis is effective in a dose range of 10 to 30 mg/day. Enhanced efficacy at doses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg. _Manic episodes in Bipolar I Disorder:_ the recommended starting dose for Alcartis is 15 mg administered on a once-a- day schedule without regard to meals as monotherapy or combination therapy (see section 5.1). Some patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg. _Recurrence prevention of manic episodes in Bipolar I Disorder:_ for preventing recurrence of manic episodes in patients who have been receiving aripiprazole as monotherapy or combination therapy, continu Citiți documentul complet